# Lecture 07: Substance Use Disorders

## Alcohol Use Disorder

### Alcohol Effects
- Causes **CNS depression** through **GABA mimetic** activity
- Can cause **metabolic acidosis**

### Alcohol Metabolism
```
Ethanol → (alcohol dehydrogenase) → Acetaldehyde → (aldehyde dehydrogenase) → Acetate
```
- Both enzymes require **NAD+**

### Acetaldehyde
- Causes: nausea/vomiting, headache, hypotension
- Inactivated via **folate binding**
- Less available when **it binds to thiamine**

---

### Medications for Alcohol Use Disorder

#### Disulfiram
| Property | Detail |
|----------|--------|
| **MOA** | Inhibits aldehyde dehydrogenase |
| **Side Effects** | Flushing, nausea, tachycardia, hypotension |
| **Other drugs with similar effect** | Metronidazole, Griseofulvin |

#### Naltrexone
| Property | Detail |
|----------|--------|
| **MOA** | Opioid antagonist |
| **How it works** | Blocks endogenous opioids and mitigates euphorigenic effects of alcohol |
| **Naltrexone vs Vivitrol** | Naltrexone = oral daily pill; Vivitrol = once monthly injectable |

#### Acamprosate
| Property | Detail |
|----------|--------|
| **MOA** | (1) Positive allosteric modulator of GABA-A receptors (2) NMDA receptor antagonist |
| **How it works** | Alcohol downregulates GABA-A receptors → causes withdrawal. Acamprosate helps restore GABA-A sensitivity |

---

## Nicotine Use Disorder

### Nicotine Properties
- Naturally occurring **alkaloid**
- Has **stimulant and anxiolytic** properties
- Acts as **agonist** at **nicotinic acetylcholine receptors**

### Nicotine Delivery Forms
- Gum, lozenge, patch (OTC)
- Nasal spray, vapor inhaler (prescription)
- **Function:** Relieves withdrawal symptoms

---

### Medications for Smoking Cessation

#### Bupropion
| Property | Detail |
|----------|--------|
| **MOA** | NE and DA reuptake inhibitor + antagonist at nicotinic ACh receptors |
| **Pathways** | Modulates pleasure pathways via dopamine; mitigates withdrawal via nAChR and dopaminergic pathways |

#### Varenicline
| Property | Detail |
|----------|--------|
| **MOA** | Partial agonist at nicotinic acetylcholine receptors |
| **Effect** | Reduces withdrawal symptoms |
| **Benefit of partial agonism** | Produces less dopamine release than nicotine → less activation of mesolimbic pathway |

---

## Opioid Use Disorder

### 3 Approved Drugs
1. Naltrexone
2. Methadone
3. Buprenorphine/Naloxone

---

### Medications for Opioid Use Disorder

#### Naltrexone
| Property | Detail |
|----------|--------|
| **MOA** | Opioid antagonist |
| **How it works** | Blocks euphoric and rewarding effects of opioids, alleviates withdrawal |

#### Methadone
| Property | Detail |
|----------|--------|
| **MOA** | Synthetic opioid that binds opioid receptors |
| **How it works** | Opioid replacement to reduce craving and withdrawal |

#### Buprenorphine/Naloxone
| Property | Detail |
|----------|--------|
| **MOA** | Partial mu opioid agonist |
| **Safety** | Ceiling effects on euphoria and respiratory depression |
| **Delivery** | Sublingual product (dissolves under tongue) |

---

## Summary Tables

### Alcohol Use Disorder Medications
| Drug | MOA | Key Point |
|------|-----|-----------|
| **Disulfiram** | Inhibits aldehyde dehydrogenase | Causes aversive reaction to alcohol |
| **Naltrexone** | Opioid antagonist | Blocks euphoria; available as daily pill or monthly injection (Vivitrol) |
| **Acamprosate** | GABA-A PAM + NMDA antagonist | Restores GABA sensitivity |

### Nicotine Use Disorder Medications
| Drug | MOA | Key Point |
|------|-----|-----------|
| **Nicotine replacement** | nAChR agonist | Relieves withdrawal |
| **Bupropion** | NE/DA reuptake inhibitor + nAChR antagonist | Dual mechanism |
| **Varenicline** | Partial nAChR agonist | Less mesolimbic activation than nicotine |

### Opioid Use Disorder Medications
| Drug | MOA | Key Point |
|------|-----|-----------|
| **Naltrexone** | Opioid antagonist | Blocks euphoria |
| **Methadone** | Full opioid agonist | Replacement therapy |
| **Buprenorphine/Naloxone** | Partial mu agonist | Ceiling effect on respiratory depression; sublingual |
